Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YONSA Extension Study in mCRPC
NCT02962284Phase 2Completed
- Sponsor
- Sun Pharma
- Start
- Nov 2016
- Primary completion
- Mar 2018
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of abiraterone in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Sun Pharma. Primary endpoint: Number of Subjects With Adverse Events at 1 year. Started Nov 2016; status: completed.
02
Drugs
abiraterone
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02962284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02962284.